LivaNova PLC (LIVN) Operating Margin
- Operating margin · 12 months: Value 12.74%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 12.74% | Operating income / revenue. Period ending 2026-06-30. $187.54M ÷ $1.47B × 100 ≈ 12.74% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 187.54M USD | Operating Income (Loss) |
| Revenue | 1.47B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 469.47M USD | Cost of Goods and Services Sold |
| Research and development | 213.06M USD | Research and Development Expense |
| Selling, general and administration | 583.58M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $187.54M | $1.47B | $469.47M | $213.06M | $583.58M | 12.74% |
| 2026-03-31 | $192.24M | $1.43B | $466.09M | $206.58M | $563.24M | 13.41% |
| 2025-12-31 | $199.39M | $1.39B | $448.18M | $185.76M | $548.81M | 14.36% |
| 2025-09-30 | $193.83M | $1.35B | $434.50M | $176.95M | $536.09M | 14.37% |
| 2025-06-30 | $175.44M | $1.31B | $418.69M | $177.18M | $524.99M | 13.40% |
| 2025-03-31 | $161.42M | $1.28B | $391.12M | $174.73M | $530.07M | 12.66% |
| 2024-12-31 | $129.05M | $1.25B | $382.56M | $182.51M | $526.26M | 10.30% |
| 2024-09-30 | $4.04M | $1.24B | $400.05M | $185.37M | $523.98M | 0.33% |
| 2024-06-30 | $-27.12M | $1.21B | $391.51M | $183.11M | $527.11M | -2.24% |
| 2024-03-31 | $-49.91M | $1.19B | $380.48M | $189.50M | $523.86M | -4.21% |
| 2023-12-31 | $-68.50M | $1.15B | $382.30M | $193.82M | $518.13M | -5.94% |
| 2023-09-30 | $33.45M | $1.12B | $353.69M | $192.58M | $504.40M | 2.99% |
| 2023-06-30 | $-102.98M | $1.08B | $351.06M | $181.77M | $484.24M | -9.49% |
| 2023-03-31 | $-88.60M | $1.05B | $332.18M | $164.87M | $474.85M | -8.48% |
| 2022-12-31 | $-76.75M | $1.02B | $314.58M | $155.81M | $469.24M | -7.51% |
| 2022-09-30 | $-65.96M | $1.02B | $291.64M | $154.97M | $474.07M | -6.49% |
| 2022-06-30 | $82.44M | $1.02B | $294.50M | $161.38M | $468.48M | 8.10% |
| 2022-03-31 | $14.42M | $1.03B | $316.91M | $179.71M | $474.75M | 1.40% |
| 2021-12-31 | $-784.00K | $1.04B | $329.37M | $183.41M | $471.90M | -0.08% |
| 2021-09-30 | $-269.14M | $1.03B | $330.81M | $183.79M | $443.53M | -26.01% |
| 2021-06-30 | $-294.52M | $1.02B | $340.15M | $189.03M | $438.52M | -28.83% |
| 2021-03-31 | $-274.89M | $939.45M | $318.36M | $161.63M | $420.21M | -29.26% |
| 2020-12-31 | $-269.86M | $934.24M | $308.06M | $152.90M | $427.77M | -28.89% |
| 2020-09-30 | $-166.11M | $952.28M | (m) | $134.29M | $448.03M | -17.44% |
| 2020-06-30 | $-132.84M | $980.80M | (m) | $132.82M | $471.85M | -13.54% |
| 2020-03-31 | $-147.48M | $1.08B | (m) | $142.22M | $501.01M | -13.71% |
| 2019-12-31 | $-168.87M | $1.08B | (m) | $149.89M | $506.54M | -15.58% |
| 2019-09-30 | $-301.35M | $1.09B | $336.25M | $161.66M | $498.16M | -27.56% |
| 2019-06-30 | $-332.86M | $1.10B | $344.42M | $158.18M | $490.28M | -30.34% |
| 2019-03-31 | $-281.38M | $1.11B | $361.47M | $157.85M | $486.51M | -25.41% |
| 2018-12-31 | $-248.07M | $1.11B | $361.81M | $146.02M | $464.97M | -22.41% |
| 2018-09-30 | $46.51M | (m) | $372.55M | $140.92M | $444.49M | (m) |
| 2018-06-30 | $82.28M | (m) | $366.00M | $121.41M | $426.56M | (m) |
| 2018-03-31 | $88.45M | $1.04B | $358.03M | $121.03M | $397.38M | 8.54% |
| 2017-12-31 | $95.67M | $1.01B | $353.40M | $109.66M | $380.56M | 9.45% |
| 2017-09-30 | $45.30M | $1.23B | $429.89M | $132.43M | $477.43M | 3.69% |
| 2017-06-30 | $36.23M | $1.21B | $428.12M | $133.21M | $465.49M | 2.99% |
| 2017-03-31 | $27.10M | $1.21B | $449.88M | $120.42M | $465.76M | 2.24% |
| 2016-12-31 | $-27.62M | $1.21B | $471.99M | $122.45M | $469.23M | -2.28% |
| 2016-10-18 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-10-18 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-07-24 | (m) | $300.56M | (m) | (m) | (m) | (m) |
| 2015-04-24 | $88.65M | $291.56M | $27.31M | $43.28M | $123.62M | 30.41% |
| 2015-01-23 | (m) | $292.33M | (m) | (m) | (m) | (m) |
| 2014-12-26 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-10-24 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-07-25 | (m) | $285.15M | (m) | (m) | (m) | (m) |
| 2014-04-25 | $80.01M | $282.01M | $27.36M | $46.56M | $120.64M | 28.37% |
| 2014-01-24 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-10-25 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-07-26 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-04-26 | $78.35M | $254.32M | $21.91M | $41.55M | $112.52M | 30.81% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |